- Home
- ZVRA vs RIGL Comparison
ZVRA vs RIGL Comparison
Compare ZVRA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZVRA | RIGL |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.9M | 564.7M |
| IPO Year | 2015 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ZVRA | RIGL |
|---|---|---|
| Price | $10.10 | $29.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $23.00 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 712.5K | 319.3K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 159.21 | ★ 1867.68 |
| EPS | 1.35 | ★ 19.48 |
| Revenue | $106,470,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $53.42 | $12.75 |
| P/E Ratio | $7.46 | ★ $1.51 |
| Revenue Growth | ★ 350.91 | 64.15 |
| 52 Week Low | $7.16 | $16.88 |
| 52 Week High | $13.16 | $52.24 |
Technical Indicators
Market Signals| Indicator | ZVRA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 48.14 |
| Support Level | $8.25 | $28.08 |
| Resistance Level | $11.07 | $30.59 |
| Average True Range (ATR) | 0.41 | 1.11 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 39.32 | 23.14 |
Price Performance
Historical ComparisonAbout ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.